MicroRNA在弥漫大B细胞淋巴瘤诊断预后方面的研究进展  

Progress of microRNA in Diagnosis and Prognosis of Diffuse Large B Cell Lymphoma——Review

作　　者：俞心念[1] 陈宝安[1] 

机构地区：[1]东南大学医学院附属中大医院血液科(江苏医学重点学科),江苏南京210009

出　　处：《中国实验血液学杂志》2013年第5期1351-1355,共5页Journal of Experimental Hematology

基　　金：国家自然和学基金(编号:81170492);国家973科技计划项目(编号:2010CB732404);江苏省医学重点学科(编号:2011-12)

摘　　要：microRNA(miRNA)是一类长度只有19-25个核苷酸的内源性小分子非编码RNA,miRNA通过和靶基因mRNA3’UTR的互补序列的不完全结合来调控一系列的基因表达,包括细胞增殖、分化、凋亡、干细胞发育。近年来研究发现,许多miRNA在肿瘤发生与发展中有着特殊的基因调控作用,已经被用作肿瘤治疗目标和预后标记物。本文将回顾弥漫大B细胞淋巴瘤(DLBCL)发生中miRNA重要的基因调控作用,以及miRNA在DLBCL的分型与诊断、治疗及预后方面的近年来研究进展。MicroRNA （miRNA） is a class of naturally occurring short non-coding small molecular RNA with 19 - 25 nucleotide. MiRNA can regulate gene expression through incompletely binding to complementary sequences in the 3＇ UTR of target mRNA. MiRNA plays key regulatory role in a diverse rang of pathways, including cell proliferation, differentiation, apoptosis, stem cell development. Many studies have shown that many miRNA have a special role of gene regulation in cancer development and have been used as therapeutic targets and diagnostic markers of cancer. This review focuses on recent advances of studies on miRNA involved in tumorigenesis, and in classification, diagnosis, therapy and prognosis of DLBCL.

关 键 词：MICRORNA 弥漫大B细胞淋巴瘤 淋巴瘤预后 

分 类 号：R733.1[医药卫生—肿瘤]